These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28387386)

  • 1. Notable deals in the pharmaceutical industry in the fourth quarter of 2016.
    D'Souza P
    Drugs Today (Barc); 2017 Jan; 53(1):75-82. PubMed ID: 28387386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Notable deals in the pharmaceutical industry in the first quarter of 2017.
    Cruces E
    Drugs Today (Barc); 2017 Jun; 53(6):357-365. PubMed ID: 28799581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Notable licensing deals in the biopharma industry in the second quarter of 2017.
    D'Souza P
    Drugs Today (Barc); 2017 Aug; 53(8):453-458. PubMed ID: 29119150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Notable deals in the pharmaceutical industry in the first quarter of 2016.
    Cruces E
    Drugs Today (Barc); 2016 Aug; 52(8):453-459. PubMed ID: 27722213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Notable deals in the pharmaceutical industry in the second quarter of 2016.
    D'Souza P
    Drugs Today (Barc); 2016 Aug; 52(8):461-465. PubMed ID: 27722214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Notable deals in the pharmaceutical industry in the third quarter of 2016.
    Cruces E
    Drugs Today (Barc); 2016 Oct; 52(10):569-575. PubMed ID: 27910965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Notable licensing deals in the biopharma industry in the third quarter of 2017.
    D'Souza P
    Drugs Today (Barc); 2017 Oct; 53(10):553-557. PubMed ID: 29286057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Life sciences licensing deals in the fourth quarter of 2017: updates and trends.
    D'Souza P
    Drugs Today (Barc); 2018 Feb; 54(2):169-175. PubMed ID: 29637940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Life sciences licensing deals in the second quarter of 2018: updates and trends.
    D'Souza P
    Drugs Today (Barc); 2018 Oct; 54(10):629-637. PubMed ID: 30398483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costing drug development.
    Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
    [No Abstract]   [Full Text] [Related]  

  • 11. Deals landscape: notable deals in the pharmaceutical industry in the first quarter of 2008.
    Shumoogam J; Al-Shamahi A
    IDrugs; 2008 May; 11(5):351-5. PubMed ID: 18465677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Life sciences licensing deals in the first quarter of 2018: updates and trends.
    Cruces E
    Drugs Today (Barc); 2018 Jun; 54(6):381-391. PubMed ID: 29998229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research.
    Cockburn IM; Henderson RM
    J Health Econ; 2001 Nov; 20(6):1033-57. PubMed ID: 11758047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality.
    Outterson K; Gopinathan U; Clift C; So AD; Morel CM; Røttingen JA
    PLoS Med; 2016 Jun; 13(6):e1002043. PubMed ID: 27299990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Returns to R&D on new drug introductions in the 1980s.
    Grabowski HG; Vernon JM
    J Health Econ; 1994 Dec; 13(4):383-406. PubMed ID: 10140531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antibiotic pipeline: reviving research and development and speeding drugs to market.
    Luepke KH; Mohr JF
    Expert Rev Anti Infect Ther; 2017 May; 15(5):425-433. PubMed ID: 28306360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fewer new drugs from the pharmaceutical industry.
    Taylor D
    BMJ; 2003 Feb; 326(7386):408-9. PubMed ID: 12595352
    [No Abstract]   [Full Text] [Related]  

  • 18. Deals landscape: notable deals in the pharmaceutical industry in the third quarter of 2008.
    Glah D; Tear S
    IDrugs; 2008 Nov; 11(11):841-5. PubMed ID: 19024888
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug costs: research and development costs: the great illusion.
    Prescrire Int; 2004 Feb; 13(69):32-6. PubMed ID: 15055226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncology drug market worth predicted to increase.
    Burki TK
    Lancet Oncol; 2015 Jan; 16(1):e10. PubMed ID: 25638545
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.